80% of those who have had COVID-19 face disorders of the nervous system

According to a study by Gradus Research* commissioned by the pharmaceutical company Darnitsa, the most common symptoms experienced by patients with COVID-19 after recovery are weakness (59%), rapid fatigue (55%) and no-load fatigue (46%).

The research company Gradus Research * commissioned by the pharmaceutical company "Darnitsa" to study the prevalence of post-COVID-19 symptoms in Ukraine. "Post-COVID-19 syndrome" is the presence of symptoms of the disease even after 12 weeks from the moment of infection. The syndrome can develop in people who have had a severe course of coronavirus infection, and in people who have had mild or moderate symptoms.

The TOP-3 most common categories of symptoms of post-COVID-19 syndrome experienced by patients after recovery include symptoms that are related to the nervous system (80%), psychoemotional state (65%) and symptoms from the respiratory system (60%).

The most common symptoms experienced by COVID-19 patients after recovery are weakness (59%), rapid fatigue (55%), no-load fatigue (46%), loss of smell (39%), headache/migraine (37%), joint pain (30%), anxiety (28%), memory loss (27%), loss of taste (27%), high/low blood pressure (25%).

Among those who have experienced post-COVID-19 syndrome, 43% have lost all its symptoms, and 44% are still affected by certain symptoms. The most popular ways to overcome the symptoms that patients used are the use of vitamins, dietary supplements (40%), as well as taking medications (29%).

People who experienced symptoms of post-COVID-19 syndrome had a more tolerant attitude towards themselves from their own family members (48% were sympathetic), compared with friends (34%) or colleagues (28%).

The vast majority (74%) of respondents follow news related to COVID-19, most often using social networks and television (58% and 48%, respectively).

For those who have experienced post-COVID-19 syndrome, the most popular information related to the disease is information about the treatment of COVID-19/post-COVID syndrome (12%). As previously reported, the pharmaceutical company "Darnitsa" has launched an information resource about post-covid. On the platform postcovid.darnitsa.ua** provides expert, verified information about post-COVID-19 and ways to overcome it. The uniqueness of the resource lies in the fact that "Darnitsa" collects, analyzes and systematizes international practice and research and makes it accessible to a wide audience. Every word and every piece of advice is backed up by evidence-based medicine, and information about symptoms is updated regularly.

"The pharmaceutical company "Darnitsa" continues to introduce a wide audience to current issues related to post-COVID-19 syndrome. In particular, we conducted a study to understand the real state of affairs with post-COVID-19 syndrome in Ukraine and see a great demand for information on this issue, which is why we continue to work with our portal postcovid.darnitsa.ua**,  filling it with up-to-date expert information from international sources," said Ihor Nykyforchyn, medical director of the pharmaceutical company "Darnitsa".

Information.

Private Joint Stock Company Pharmaceutical company "Darnitsa" was founded in 1930 and this year celebrates its 91st anniversary. Since 1998, "Darnitsa" has been the leader in Ukraine in terms of drug production in physical terms. Strategic areas of portfolio development include cardiology, neurology, and pain management. During 2015-2020, "Darnitsa" launched 50 pharmaceutical brands on the market.

*Gradus Research commissioned by the pharmaceutical company "Darnitsa", 1527 interviews, men and women aged 18 to 60 years living in Kharkiv, Kyiv, Lviv, Odesa, Zaporozhya and Dnipro, November 2-4, 2021.

**The information on this website is purely informational in nature and cannot be used for self-diagnosis or self-medication.